Shareholders Equity: The sum of preferred and common equity items.
Alto Neuroscience, Inc. (ANRO) had Shareholders Equity of $151.14M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-63.24M |
|
-- |
|
-- |
|
$66.36M |
|
$-66.36M |
|
$3.13M |
|
$-63.24M |
|
$-63.24M |
|
$-63.24M |
|
$-63.24M |
|
$-63.24M |
|
$-63.24M |
|
$-66.36M |
|
$-65.70M |
|
28.85M |
|
28.85M |
|
$-2.19 |
|
$-2.19 |
|
| Balance Sheet Financials | |
$177.72M |
|
$1.87M |
|
$6.97M |
|
$184.69M |
|
$11.32M |
|
$18.40M |
|
$22.22M |
|
$33.55M |
|
$151.14M |
|
$151.14M |
|
|
Shareholders Equity |
$151.14M |
31.92M |
|
| Cash Flow Statement Financials | |
$-51.77M |
|
$-0.02M |
|
$60.08M |
|
$168.73M |
|
$176.98M |
|
$8.26M |
|
$8.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.69 |
|
-- |
|
-- |
|
0.11 |
|
0.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-41.84% |
|
-41.84% |
|
-34.24% |
|
-37.30% |
|
$4.73 |
|
$-1.80 |
|
$-1.79 |
|